Please use this identifier to cite or link to this item:
Title: What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?
Authors: Gollan, J.K.
Fava, M.
Kurian, B.
Wisniewski, S.R.
Rush, A.J. 
Daly, E.
Miyahara, S.
Trivedi, M.H.
Keywords: Anxiety
Issue Date: Feb-2012
Citation: Gollan, J.K., Fava, M., Kurian, B., Wisniewski, S.R., Rush, A.J., Daly, E., Miyahara, S., Trivedi, M.H. (2012-02). What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?. Depression and Anxiety 29 (2) : 94-101. ScholarBank@NUS Repository.
Abstract: Objective: To evaluate the prevalence of new onset or worsening of anxiety symptoms, as well as their clinical implications, during the first 2 weeks of Selective Serotonin Reuptake Inhibitor (SSRI) pharmacotherapy for depression. Method: Adult outpatients with nonpsychotic major depressive disorder were enrolled in an 8-week acute phase SSRI treatment trial at 15 clinical sites across the United States. Worsening anxiety was defined as a greater than 2-point increase on the Beck Anxiety Inventory (BAI) between baseline and Week 2. New onset of anxiety symptoms was ascribed when the BAI baseline rating was 0 and the Week 2 value was greater or equal to 2 points on the BAI. Results: Overall, after 2 weeks of treatment, 48.8% (98 of 201 participants) reported improvement in anxiety symptoms, 36.3% (73 of 201) reported minimal symptom change, and 14.9% (30 of 201) reported worsening of anxiety symptoms. No association was found between change in anxiety symptoms within the first 2 weeks and change in depressive symptoms or remission at the end of 8 weeks of treatment. For participants with clinically meaningful anxiety symptoms at baseline, however, worsening of anxiety during the first 2 weeks of treatment was associated with worsening depressive symptoms by 8 weeks (P5.054). Conclusions: The trajectory of anxiety symptom change early in SSRI treatment is an important indicator of eventual outcome for outpatients with major depression and baseline anxiety symptoms. © 2011 Wiley Periodicals, Inc.
Source Title: Depression and Anxiety
ISSN: 10914269
DOI: 10.1002/da.20917
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Nov 7, 2018


checked on Nov 16, 2017

Page view(s)

checked on Sep 28, 2018

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.